oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Company profile
Ticker
OCX
Exchange
Website
CEO
Ronald Asbury Andrews
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Oncocyte Corp, OncoCyte Corp
SEC CIK
Corporate docs
Subsidiaries
Insight Genetics, Inc. • Chronix Biomedical, Inc. • Chronix Biomedical GmbH ...
OCX stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
23 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Oncocyte Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K/A
Changes in Registrant's Certifying Accountant
10 Oct 23
8-K
Changes in Registrant's Certifying Accountant
5 Oct 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
8-K
Other Events
28 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Oncocyte Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
ONCOCYTE ANNOUNCES 1-for-20 reverse stock split
24 Jul 23
Transcripts
OCX
Earnings call transcript
2023 Q3
9 Nov 23
OCX
Earnings call transcript
2023 Q2
10 Aug 23
OCX
Earnings call transcript
2023 Q1
11 May 23
OCX
Earnings call transcript
2022 Q4
3 Apr 23
OCX
Earnings call transcript
2022 Q3
11 Nov 22
OCX
Earnings call transcript
2022 Q2
11 Aug 22
OCX
Earnings call transcript
2022 Q1
12 May 22
OCX
Earnings call transcript
2021 Q4
11 Mar 22
OCX
Earnings call transcript
2021 Q3
10 Nov 21
OCX
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
SC 13G/A
PURA VIDA INVESTMENTS, LLC
14 Feb 24
SC 13G/A
AWM Investment Company, Inc.
14 Feb 24
4
James Yang Liu
12 Oct 23
4
Josh Riggs
17 Aug 23
4
John Peter Gutfreund
3 Jul 23
4
Andrew Arno
27 Jun 23
4
Andrew J. Last
27 Jun 23
4
ALFRED D KINGSLEY
27 Jun 23
4
LOU SILVERMAN
27 Jun 23
4
ALFRED D KINGSLEY
15 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.48 mm | 15.48 mm | 15.48 mm | 15.48 mm | 15.48 mm | 15.48 mm |
Cash burn (monthly) | 1.20 mm | 1.52 mm | 2.17 mm | 1.74 mm | 753.00 k | 2.37 mm |
Cash used (since last report) | 7.10 mm | 9.05 mm | 12.90 mm | 10.35 mm | 4.48 mm | 14.07 mm |
Cash remaining | 8.38 mm | 6.43 mm | 2.58 mm | 5.13 mm | 11.01 mm | 1.41 mm |
Runway (months of cash) | 7.0 | 4.2 | 1.2 | 2.9 | 14.6 | 0.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 7 |
Closed positions | 12 |
Increased positions | 14 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 21.08 bn |
Total shares | 162.65 mm |
Total puts | 0.00 |
Total calls | 10.10 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Broadwood Partners | 57.13 mm | $18.14 mm |
Broadwood Capital | 50.18 mm | $11.54 bn |
AWM Investment | 14.19 mm | $3.26 bn |
Pura Vida Investments | 13.63 mm | $3.13 bn |
Halle Special Situations Fund | 7.13 mm | $0.00 |
Norfield Capital | 6.60 mm | $3.10 mm |
Vanguard | 4.36 mm | $1.00 bn |
MS Morgan Stanley | 2.79 mm | $641.92 mm |
Defender Capital | 2.33 mm | $535.11 mm |
Geode Capital Management | 1.23 mm | $282.57 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Oct 23 | James Yang Liu | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 3.11 | 8,482 | 26.38 k | 8,482 |
15 Aug 23 | Josh Riggs | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 3.34 | 40,000 | 133.60 k | 40,000 |
30 Jun 23 | John Peter Gutfreund | Common Stock, no par value | Other | Dispose J | Yes | No | 0 | 3,085,047 | 0.00 | 0 |
30 Jun 23 | John Peter Gutfreund | Warrants to Purchase Common Stock Common Stock | Other | Dispose J | Yes | No | 1.53 | 3,564,728 | 5.45 mm | 0 |
23 Jun 23 | Arno Andrew | Common Stock, no par value | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 703,133 |
23 Jun 23 | Arno Andrew | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.2 | 135,000 | 27.00 k | 135,000 |
23 Jun 23 | Last Andrew J. | Common Stock, no par value | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 90,170 |
23 Jun 23 | Last Andrew J. | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.2 | 90,000 | 18.00 k | 90,000 |